Clinuvel Pharmaceuticals Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Clinuvel Pharmaceuticals heeft een totaal eigen vermogen van A$203.0M en een totale schuld van A$0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk A$231.1M en A$28.1M. De EBIT Clinuvel Pharmaceuticals is A$48.6M waardoor de rentedekking -16.9 is. Het heeft contanten en kortetermijnbeleggingen van A$183.9M.

Belangrijke informatie

Verhouding schuld/eigen vermogen

AU$0

Schuld

Rente dekkingsratio	-16.9x
Contant	AU$183.87m
Aandelen	AU$203.01m
Totaal verplichtingen	AU$28.11m
Totaal activa	AU$231.12m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity

Aug 11

An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued

Nov 18

Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Oct 20

Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?

Jul 30

Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate

Feb 27

Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?

Dec 14

This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid

Nov 03

A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Sep 23

Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today

Jul 23

With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting

Apr 10

Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?

Mar 06

Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts

Feb 27

What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?

Feb 20

Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain

Feb 01

Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Jan 14

We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide

Dec 28

Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Dec 10

What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition

Nov 21

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( A$222.1M ) CUV } overtreffen de korte termijn passiva ( A$25.2M ).

Langlopende schulden: De kortetermijnactiva CUV ( A$222.1M ) overtreffen de langetermijnschulden ( A$2.9M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: CUV is schuldenvrij.

Schuld verminderen: CUV heeft de afgelopen 5 jaar geen schulden gehad.

Schuldendekking: CUV heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.

Rentedekking: CUV heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.

Clinuvel Pharmaceuticals Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

CLINUVEL Files Canadian New Drug Submission for SCENESSE® in EPP

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 16, 2024

Dividend of AU$0.05 announced

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 17%

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Aug 29, 2024

Price target increased by 18% to AU$30.32

Clinuvel Pharmaceuticals Limited Announces Change of Company Secretary

CLINUVEL Announces A Novel Clinical Program

Price target decreased by 7.4% to AU$25.01

First half 2024 earnings released: EPS: AU$0.22 (vs AU$0.23 in 1H 2023)

Clinuvel Pharmaceuticals Limited to Report First Half, 2024 Results on Feb 22, 2024

Price target increased by 13% to AU$31.12

Price target decreased by 7.2% to AU$27.50

Clinuvel Pharmaceuticals Limited Announces Board Changes

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 31, 2023

Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2023, Payable on September 20, 2023

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Aug 29, 2023

If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity

Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?

Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Investor sentiment deteriorates as stock falls 20%

Now 22% undervalued

First half 2023 earnings released: EPS: AU$0.23 (vs AU$0.12 in 1H 2022)

Clinuvel Pharmaceuticals Ltd Announces the Completion of Manufacture of the First cGMP Batch of PRÉNUMBRA® Instant

Clinuvel Pharmaceuticals Limited Announces First Positive Results from Study Evaluating the Protective Effects of Afamelanotide on Skin Exposed to Ultraviolet Radiation

Price target increased by 11% to AU$28.94

Clinuvel Pharmaceuticals Limited Announces Neuracthel Manufacturing Processes Advance

Clinuvel Pharmaceuticals Limited Shares the First Results of Phase II Study Evaluating Afamelanotide in Patients with Xeroderma Pigmentosum

An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued

No independent directors

Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Clinuvel Pharmaceuticals Limited Announces Enrollment of First Patient in New Clinical Study CUV104

Investor sentiment improved over the past week

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 26, 2022

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2022, Payable on September 21, 2022

Now 20% undervalued

Investor sentiment improved over the past week

Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?

CLINUVEL PHARMACEUTICALS LIMITED Intends to Evaluate its Drug Candidate PRÉNUMBRA Instant (Afamelanotide) as A Treatment for Patients Diagnosed with Arterial Ischaemic Stroke (AIS) in its Next Clinical Trial (CUV803)

Non-Executive Director recently sold AU$356k worth of stock

CLINUVEL Progresses CUV104 Vitiligo Study

CLINUVEL Releases Positive Final Results of the Open Label Pilot Study (CUV801) in Arterial Ischemic Stroke

No independent directors

Clinuvel Pharmaceuticals Ltd Appoints Andrew Likierman as New Non-Executive Director

Clinuvel Pharmaceuticals Limited Announces First XP-V Patient Treated in Third CUV DNA Repair Study

CEO, MD & Director recently sold AU$1.1m worth of stock

Now 22% undervalued after recent price drop

Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to AU$27.32

Investor sentiment deteriorated over the past week

Clinuvel Pharmaceuticals Limited Completes Enrolment in CUV801 Stroke Study

Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?

This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid

A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Full year 2021 earnings released: EPS AU$0.50 (vs AU$0.31 in FY 2020)

Investor sentiment improved over the past week

Price target increased to AU$33.92

Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today

CEO, MD & Director recently sold AU$3.7m worth of stock

Non-Executive Director recently sold AU$692k worth of stock

Clinuvel Pharmaceuticals Limited Announces First Stroke Patient Treated with Afamelanotide

CEO, MD & Director recently sold AU$3.1m worth of stock

With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting

Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?

CEO, MD & Director recently sold AU$2.6m worth of stock

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2021 Results on Aug 31, 2021

Investor sentiment improved over the past week

Analysts update estimates

Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts

Revenue and earnings miss expectations